0A3M Stock Chart & Stats
$89.83
-$1.96(-2.14%)
At close: 4:00 PM EDT
$89.83
-$1.96(-2.14%)
Day’s Range― - ―
52-Week Range$79.51 - $123.69
Previous CloseN/A
Volume819.00
Average Volume (3M)1.44K
Market Cap
$22.91B
Enterprise Value$5.96K
Total Cash (Recent Filing)$14.65B
Total Debt (Recent Filing)$303.12M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 03, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding252,884,260
10 Day Avg. Volume1,841
30 Day Avg. Volume1,437
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$125.25Price Target Upside39.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.55
Revenue Forecast (FY)$2.16B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityA very low debt-to-equity ratio and strong equity base give BioNTech durable financial flexibility to fund multi-year R&D programs, support manufacturing scale-up and absorb post-peak revenue shocks without immediate refinancing risk, enabling sustained investment in oncology.
Free Cash Flow Turned Positive RecentlyThe shift to positive free cash flow in 2025 and improvement in trailing cash generation provide a more sustainable funding source for development programs and commercialization investments, reducing near-term dilution risk and supporting disciplined capital actions like the announced buyback.
Advancing Late-stage Oncology Pipeline And PartnershipsStrong interim Phase 2 results and a multi-trial Phase 3 program (with partners like BMS) mark a structural shift from vaccine dependency toward a diversified oncology franchise. Multiple pivotal trials increase the probability of new, repeatable revenue streams and long-term strategic positioning in immuno-oncology.
Bears Say
Large, Persistent Operating And Net LossesDespite very high gross margins, operating costs have overwhelmed profitability for multiple years. Persistent losses erode retained earnings over time, can force reprioritization of pipeline projects, and raise the risk that the company must cut spend or seek external funding if product commercialization lags.
Revenue Decline And Vaccine Demand VolatilityHistoric reliance on COVID-19 vaccine volumes creates structural revenue volatility as demand normalizes. Until late-stage oncology assets reach approval and commercialization, the company faces uneven top-line performance that complicates long-range planning and increases earnings unpredictability.
High R&D-driven Cash BurnAggressive R&D investment is essential for pipeline progression but materially increases cash burn and operating losses. Over multiple quarters this can deplete resources, force deprioritization of programs, or require partnerships and capital events if clinical timelines slip or approvals are delayed.
BioNTech SE News
0A3M FAQ
What was Biontech Se Sponsored Adr’s price range in the past 12 months?
Biontech Se Sponsored Adr lowest share price was $79.51 and its highest was $123.69 in the past 12 months.
What is Biontech Se Sponsored Adr’s market cap?
Biontech Se Sponsored Adr’s market cap is $22.91B.
When is Biontech Se Sponsored Adr’s upcoming earnings report date?
Biontech Se Sponsored Adr’s upcoming earnings report date is Nov 03, 2026 which is in 90 days.
How were Biontech Se Sponsored Adr’s earnings last quarter?
Biontech Se Sponsored Adr released its earnings results on Aug 04, 2026. The company reported -$3.736 earnings per share for the quarter, missing the consensus estimate of -$2.421 by -$1.314.
Is Biontech Se Sponsored Adr overvalued?
According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued.
Does Biontech Se Sponsored Adr pay dividends?
Biontech Se Sponsored Adr does not currently pay dividends.
What is Biontech Se Sponsored Adr’s EPS estimate?
Biontech Se Sponsored Adr’s EPS estimate is 0.89.
How many shares outstanding does Biontech Se Sponsored Adr have?
Biontech Se Sponsored Adr has 252,884,260 shares outstanding.
What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?
Biontech Se Sponsored Adr reported an EPS of -$3.736 in its last earnings report, missing expectations of -$2.421. Following the earnings report the stock price went down -1.934%.
Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?
Currently, no hedge funds are holding shares in GB:0A3M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.25 (39.43% Upside)
$125.25 (39.43% Upside)
Blogger Sentiment
Bullish
GB:0A3M Sentiment 78%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.12%
Trailing 12-Months
Company Description
Biontech Se Sponsored Adr
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
0A3M Company Deck
0A3M Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.View all GB:0A3M earnings summaries0A3M Stock 12 Month Forecast
Average Price Target
$125.25
▲(39.43% Upside)